IceCure adds Legacy Health as U.S. site for ProSense ChoICE low-risk breast cancer study
ICCM•IceCure added Legacy Health in Portland as a U.S. site for its ongoing ChoICE post-market study of ProSense cryoablation in low-risk breast cancer. The study plans to enroll about 400 patients across up to 30 U.S. clinical sites; results have not been presented.
1. Study expands to Portland
Legacy Health in Portland has joined the ChoICE study, which is evaluating ProSense cryoablation in low-risk breast cancer. The study aims to enroll about 400 patients across up to 30 U.S. sites under a standardized protocol and is intended to generate additional real-world evidence on safety and effectiveness.
